Basic Information

Gene symbol VEGFA Synonyms L-VEGF, MVCD1, VEGF, VPF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description vascular endothelial growth factor A

GTO ID GTC0024
Trial ID NCT00242580
Disease Macular Degeneration
Altered gene VEGFA
Therapeutic/Target gene Target gene
TherapyAptamer
Treatment Macugen|pegaptanib|EYE001
Co-treatment Verteporfin|Triamcinolone acetonide
PhasePhase3
Recruitment statusCompleted
TitleA 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne Plus Intravitreal Pegaptanib(Macugen) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Year2005
CountryUnited States
Company sponsorNovartis Pharmaceuticals
Other ID(s)CBPD952E2202

Clinical Result

Cohort1: Triamcinolone acetonide 1 mg
Administration route intravenous infusion|intravitreal injection
Pts 32
Age Adult, Older_Adult
Outcome Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline:Measure Type: Number:59.4
Adverse reactions 11/32(Cardiac disorders; Gastrointestinal disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Vascular disorders)
Cohort2: Triamcinolone acetonide 4 mg
Administration route intravenous infusion|intravitreal injection
Pts 41
Age Adult, Older_Adult
Outcome Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline:Measure Type: Number:63.4
Adverse reactions 9/41(Cardiac disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Infections and infestations; Injury, poisoning and procedural complications; Nervous system disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)
Cohort3: Pegaptanib 0.3 mg
Administration route intravenous infusion|intravitreal injection
Pts 38
Age Adult, Older_Adult
Outcome Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline:Measure Type: Number:71.1
Adverse reactions 10/38(Cardiac disorders; Ear and labyrinth disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Nervous system disorders; Renal and urinary disorders; Vascular disorders)

Relationship Graph

Overview of Knowledge Graph